Adherence to PTH(1-84) Treatment (FP-002-IM)

Adherence to PTH(1-84) Treatment in Europe. A Non-interventional Cohort Study Collecting Safety Information and Examining Reasons and Predictors for Adherence to PTH(1-84) Treatment in Usual Clinical Settings

The primary objective is:

1) to describe adherence (and the main factors influencing adherence) to PTH(1-84) treatment when prescribed in a normal clinical setting.

The secondary objectives are:

1. to describe the demographics and clinical characteristics of the patients that in a normal clinical setting are started on a treatment regimen with PTH(1-84)
2. to describe (using available data) the long term treatment effectiveness during the 24 months following initiation of PTH(1-84) treatment in a normal clinical setting
3. to monitor safety for 24 months following initiation of PTH(1-84) treatment in a patient in a normal clinical setting.

Inclusion Criteria:

• According to the current Summary of Product Characteristics (SmPC)
• PTH(1-84) treatment initiated within one month preceding enrolment
• The patient's written informed consent to direct access and data processing must be obtained.

Exclusion Criteria:

• According to the current SmPC
• The patient cannot participate in a clinical trial with PTH (all other trials allowed).